This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The S&P 500's Wild August, HubSpot Stock & More - Free Lunch
by Benjamin Rains
A look at the S&P 500's wild August, GDP growth estimates and consumer confidence updates, Johnson & Johnson (JNJ) and news of a potential Philip Morris International (PM) and Altria (MO) merger, and why HubSpot (HUBS) is a Zacks Rank #1 (Strong Buy) stock - Free Lunch
Lilly's (LLY) Taltz Gets FDA Nod for Ankylosing Spondylitis
by Zacks Equity Research
The FDA approves Eli Lilly's (LLY) Taltz injection for the treatment of adult patients with active ankylosing spondylitis. Shares rise.
AstraZeneca's Farxiga Gets Fast Track Tag for Renal Outcome
by Zacks Equity Research
The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to delay progression of renal failure and prevent cardiovascular and renal death in patients with chronic kidney disease.
J&J Up Despite $572M Fine in Oklahoma Opioid Abuse Case
by Zacks Equity Research
A court ordered J&J (JNJ) to pay $527 million in the Oklahoma litigation related to abuse of its opioid-based drugs. The company is facing similar litigation in multiple states.
Case-Shiller Index Nudges Up
by Zacks Equity Research
Case-Shiller Index Nudges Up
J&J to Pay $572M in Opioid Case; Plus Case-Shiller Home Price Read
by Mark Vickery
Johnson & Johnson (JNJ) now owes $572 million, as per the judge in this case, which pits J&J responsible for rampant opioid use.
J&J's (JNJ) Opioid Lawsuit Verdict in Oklahoma Due Next Week
by Zacks Equity Research
J&J (JNJ) is facing several litigation in multiple states related to abuse of its opioid-based drugs. A ruling is expected on Aug 26 in a trial filed by the state of Oklahoma.
Pharma Stock Roundup: ABBV's Rinvoq Gets FDA Nod, BAYRY to Sell Animal Health Unit
by Kinjel Shah
FDA approves AbbVie's (ABBV) upadacitinib to be marketed as Rinvoq. Bayer (BAYRY) is set to divest its Animal Health unit to Elanco for $7.6 billion in a cash-and-stock deal.
Glaxo Submits First Regulatory Application for Daprodustat
by Zacks Equity Research
Glaxo (GSK) seeks approval for its anemia candidate, daprodustat, in Japan. Moreover, once every two months administration of cabotegravir and rilpivirine shows non-inferiority to once a month administration in HIV patients in a clinical study.
Mallinckrodt (MNK) Stock Down 70.8% YTD on Numerous Lawsuits
by Zacks Equity Research
Mallinckrodt (MNK) crashes 70.8% in the year so far due to various lawsuits and litigations.
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $131.53 in the latest trading session, marking a +0.71% move from the prior day.
Endo Up on Settlement of a Few Cases Related to Opioid Drugs
by Zacks Equity Research
Endo (ENDP) finally has some good news for investors with the settlement of a few cases in Ohio related to opioid medications.
Quality ETFs for Volatile Markets
by Neena Mishra
Stocks with excellent earnings growth and strong balance sheets deliver better risk adjusted returns over the long term
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Johnson & Johnson, NVIDIA, Booking and Fidelity
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Johnson & Johnson, NVIDIA, Booking and Fidelity
Top Research Reports for Berkshire Hathaway, Johnson & Johnson & NVIDIA
by Mark Vickery
Today's Research Daily features updated research reports on 12 major stocks, including Berkshire Hathaway (BRK.B), Johnson & Johnson (JNJ) and NVIDIA (NVDA).
Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY
by Kinjel Shah
FDA approves Roche's (RHHBY) tumor-agnostic medicine, Rozlytrek, J&J's Sirturo for young TB patients.
Why Is Johnson & Johnson (JNJ) Down 1.2% Since Last Earnings Report?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study
by Zacks Equity Research
Lilly's (LLY) Taltz is an important revenue driver for Lilly. Top-line data from a study shows that Taltz helps more plaque psoriasis patients achieve 100% skin clearance compared to Tremfya.
J&J's Tuberculosis Drug Gets FDA Nod for Adolescent Patients
by Zacks Equity Research
FDA approves J&J's (JNJ) pulmonary multidrug-resistant tuberculosis tablet Sirturo (bedaquiline) for the treatment of adolescent patients.
Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pacira (PCRX) rides high on both earnings and revenue beat in the second quarter of 2019. Moreover, Exparel drives year-over-year growth.
Perrigo (PRGO) Beats on Q2 Earnings and Sales, Stock Up
by Zacks Equity Research
Perrigo (PRGO) reports encouraging second-quarter 2019 results. The Rx segment recovers on strong new product sales.
Geron (GERN) Stock Up Despite Q2 Earnings & Sales Miss
by Zacks Equity Research
Geron (GERN) posts a wider-than-expected loss in second-quarter 2019. Operating expenses increase on a year-over-year basis.
Theravance (TBPH) Q2 Loss Narrower, Revenues Beat Estimates
by Zacks Equity Research
Theravance (TBPH) reports narrower-than-expected loss and beats on sales in the second quarter of 2019.
Merck (MRK) Beats on Q2 Earnings & Sales, Raises '19 View
by Zacks Equity Research
Merck (MRK) beats estimates for earnings as well as sales in second-quarter 2019. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand. Shares up.